meg tirrell. may not sell entirely. >> may not control their destiny. the entire board would be up for election. they seem to have missed the window and, i don't know, that makes them vulnerable to delaware corp. it doesn't seem to be. i didn't see a very large insider holding base at all so it's an interesting space now, the idea of a hostile takeover in the space i find a little curious. >> look. i'm not saying i won't buy a stock specifically for a takeover and when you hear the management say we're not willing to sell or we don't want to sell. scares me a little bit. >> judgment day for tesla after gains of more than 20% in the past month. will the unveil of the new model 3 tomorrow be enough to keep themrizing the new supercharge. much more "fast money" right after this. ♪ in new york state, we believe tomorrow starts today. all across the state, the economy is growing, with creative new business incentives, the lowest taxes in decades, and new infrastructure for a new generation attracting the talent and companies of tomorrow. like in rochester, w

i think they waited a very long time. >> our meg tirrell spoke with david pyott.ing back, you said it's a caretaker roll, i guess. is that enough here? i mean, you can argue that mike pearson didn't help or people tried to point at the cfo or whatever. thgs a strategy which i'm not sure how you either double down on it and it seems like if pershing square is on the board, they supported the original strategy or perhaps want to see a continuation of that. if they don't go that route. are you suggesting they are trying to make themselves into a very different company? >> absolutely. they have an unsustainable business model that's been clear from the outset. you can't continue to run a pharmaceutical company on three% rnd and 3% tax. they became a tyco and it doesn't work. i don't think it's caretaker, i think it's a dramatic 24/7 job that someone has to do a total remake and good a sustainable new business model and back into being a real company. i think they will have to dismantle parts of the company with the $30 million in debt, staring them in the face. they'v

david morris is here senior pharmaceutical as analyst along with meg tirrell. >> where does valeant go >> it's so much changing. in a month you have an sec investigation, a 10-k that's not filed other investigations, earnings that are down 32% from a month earlier. >> either this company is a great value or going to zero. >> we don't think it's a great value. it's tough to say it will go zero. you have $32 billion in debt. there are ways they could get to that. that's not our call. our call is it's unownable. >> this suspend coverage on stock. >> there are investors that need to know. >> say there's too much stuff going on. we don't know enough to make a rating. >> this is what he's paid to do. >> with everything we know now it's worth about $30. >> let's say you're bill ackman. you own the stuff. you're stuck with it. what do you? what do you tell him? >> i think all investors whether you're bill ackman or any warren buffett, you are never stuck with a stock. make the right decision today. its where you sit right then and there. >> it becomes a very difficult

. >>> jauron mill i sigana, along with our meg tirrell. ad, meg. >> thanks for having us here. thank for coming to see us. >> our pleasure. that surprised a lot of people. they're looking for a 10 per royalty. what's your expectation? all i can tell you is we think the merck patents are invalid, and we do plan to appeal the case tess end of the day. >> i want to talk about the hepatitis-c franchise. obviously it's been the biggest driver recently, and i have to ask you about the pricing controversy. this has obviously been something that's gained congress. were you surprised that the surprise of this drug and the combination drug was such a controversy? >> well, first of all we priced it in alignment with the current standard of care at the time, even though the drug was clearly going to have a greater benefit to a greater number of people. subsequent to that, the system has worked well. we have provided additional rebates, competition has further driven down the prices. we're in this unfortunate situation where the headline of a very high

meg tirrell has a lot more on what's going on at hq. what's going on?cline yesterday, up about 2% really isn't significant or meaningful in any way but we'll keep digging on that. folks are worried about what's going to come next. there's a ticking clock on valiant right now. if you take look at the timelines that valiant laid out yesterday during its call. basically today is a very important day. if the 10 k is not filed by today and we know it won't be. that sets off a 60-day time period for them to file the 10k. and on march 30th, that sets off another 30-day timeline. what they said is they plan to start negotiations with the bank lenders in order to get a waiver for that. they hope to file their 10k in april, but they don't know for sure if they can do that because it depends on the board finishing its investigation of fi fill a door. also, of course, they have their 10q from the first quarter that's going to be delayed as well. folks are getting very, very concerned about that. that's not all they're concerned about. we had david on "squawk box" t

meg tirrell has the latest. >>> here's a look at shares of biotech medivation on the pricing of the proste cancer drug. >> holding hearings on the price of drugs is nothing new but the mechanism that these congressmen are asking to use is kind of a new thing. essentially they are asking the nih to hold a public hearing on the price of this prostate cancer drug because it has been funded by federal funds. seblly it was developed a lot in part at ucla with funds from nih and department of defense and the argument of the congressman and non-profit which is behind this petition is essentially saying this needs to be available at a reasonable price to the public because it was funded with public money and nih has the ability to come in and try to examine the price of this drug and even potentially to take away the patent protection. it is partnering with the japanese company and the argument is it's priced at $129,000 a year versus $30,000 in canadcanada. the u.s. funded the development of the drug. >> that's been the case with a lot of these. every time they point out it's so much cheaper ov

thanks so much, meg tirrell. >> we start with breaking news that we're following out of belgium.an active police operation is under way in the town of mollenbeek. new vitd video from vtm shows an apparent arrest from today's raid. it's unclear if the person taken into custody is abdeslam or someone else. police are at least looking for one more suspect. two large explosions have been heard near the house where abdeslam was arrested. he had been on the run since cape escaping capture last november. authorities believe he was the driver of the car that tooked armed gunmen to the bataclan theater in paris where 89 were killed. today's operation follows another raid earlier in week also near brussels which resulted in the death of another man whose profile matches that of an isis fighter who wanted to be a suicide attacker according to documents obtained by nbc news. we're expecting to hear from belgium's prosecutor on today's events and in a few moments they will hold a news conference. we'll bring you any headlines when it occurs. but the operation is still ongoing, there are still